Joachim Gullbo has a scientific background in development and evaluation of anti-cancer drugs, from the early stages of lead identification and in vitro assays, to toxicology and proof-of-concept investigations in animal models and clinical trials.
He has co-authored more than 75 scientific publications within the cancer field and has supervised two PhD students working with alkylating peptides.
Dr Gullbo has clinical specialist training in Clinical Pharmacology and Oncology and was earlier Head of Oncology at Uppsala University Hospital. He is currently Medical Monitor at Theradex Oncology, Princeton, US. Dr Gullbo is a scientific advisor to Oncopeptides.